Current report filing

Cover

v3.24.3
Cover
Oct. 04, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description On October 7, 2024, Sigyn Therapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) reporting that the holders of $474,793 of Original Issue Discount Senior Convertible Debentures elected to convert their debentures at an average contractual exercise price of $4.00 per share in exchange for the issuance of 118,700 shares of the Company’s Common Stock to the holders. In the Original Form 8-K the Company stated the issuance of the Common Stock was “exempt from registration pursuant to Section 4(a)(2) of the Securities Act promulgated thereunder as the Sellers are controlled by one of executive officers who is an accredited investor and familiar with the Company’s operations.” The statement that the Sellers “are controlled by one of executive officers” was in error. None of the Sellers are controlled by any of the Company’s executive officers. The correct, amended disclosure is contained in Item 3.02, below.
Document Period End Date Oct. 04, 2024
Entity File Number 000-55575
Entity Registrant Name SIGYN THERAPEUTICS, INC.
Entity Central Index Key 0001642159
Entity Tax Identification Number 84-4210559
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2468 Historic Decatur Road
Entity Address, Address Line Two Suite 140
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92106
City Area Code 619
Local Phone Number 353.0800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false